Seeking Alpha

Smith On Stocks

 
View as an RSS Feed
View Smith On Stocks' Comments BY TICKER:
Latest  |  Highest rated
  • Analysis: Northwest Biotherapeutics DCVax-L Germany Approval Under Hospital Exemption Early Access Program [View article]
    It is unusual. However, I have 99.9999999% confidence that the DMB after the efficacy analysis will recommend that the trial should continue. There will be no statement on actual efficacy data as is always the case. This would unblind the trial and would mean that it could not be used for registrational purposes.
    Mar 20 09:27 AM | Likes Like |Link to Comment
  • Neuralstem (CUR, Buy, $4.48) Publishing Of Phase 1 Results In Annals Of Neurology Causes Price Surge [View instapost]
    Remember that we are really basing our efficacy hopes on just three patients. However, the outcomes were extraordinarily good and unprecedented.
    Mar 18 09:34 AM | Likes Like |Link to Comment
  • AF strikes again [View news story]
    I think we may soon find out.
    Mar 12 01:29 PM | 3 Likes Like |Link to Comment
  • AF strikes again [View news story]
    Well, he has clearly done so in this case.
    Mar 12 12:53 PM | 1 Like Like |Link to Comment
  • AF strikes again [View news story]
    It is perfectly alright to have a negative opinion on a company. It is not alright to purposely publish false, damaging and clearly misleading information to manipulate the stock price.
    Mar 12 11:17 AM | 10 Likes Like |Link to Comment
  • AF strikes again [View news story]
    Feuerstein has been made aware that his information is incorrect, but refuses to apologize and retract. He may have overstepped. He has gone from journalism to purposely promulgating false information that has manipulated the stock price. This situation is so egregious that I would not be surprised to see the SEC get involved.
    Mar 12 11:03 AM | 13 Likes Like |Link to Comment
  • Analysis: Northwest Biotherapeutics DCVax-L Germany Approval Under Hospital Exemption Early Access Program [View article]
    Feuerstein has published clearly false and misleading information.

    He alleged that NWBO purposely delayed releasing news for two weeks on the approval of DCVax-L in Germany under the hospital exemption early access program. He states that this was done to manipulate the stock price by using the release as a “smokescreen” to divert attention away from other issues on the stock. If this allegation were correct, which it is not, would be a violation of securities law by NWBO.

    Northwest Biotherapeutics has just published a press release that shows that Feuerstein’s allegation is patently false and misleading. It clearly lays out the timeline that shows that the release of this information on March 10th was the earliest possible date that it could have done so. Feuerstein has clearly got this wrong and I would expect that he will apologize and issue a retraction.

    Northwest released a press release that clearly shows that his allegation that Northwest Biotherapeutics purposely delayed the announcement on the release of the German approval is patently false and misleading. The Company in its press release unequivocally refutes allegations made by Feuerstein in article published on Tuesday March 11. Feuerstein falsely accuses NW Bio of intentionally delaying the announcement of the Hospital Exemption approval by the Paul Ehrlich Institute (“PEI,” the FDA of Germany). Feuerstein’s accusations are factually wrong, materially misleading and reflect a lack of knowledge of German legal requirements relating to the PEI decision and the Company’s announcement.

    Feuerstein noted that the PEI decision was delivered to the Company on Friday, February 21. What Feuerstein failed to note was that the quite lengthy PEI decision document was delivered to the Company entirely in German. It required more than a week for the Company to receive the English translation. Due to the technical nature of the document, the Company had to obtain confirmation of the accuracy of the translation and confirm certain provisions of the approval. This process took several days.

    The final requirement under applicable German regulations was that the Company was required to obtain approval of the full English press release before releasing it. This was done by an independent Information Officer in Germany designated by PIE. The approval of the German reviewer was received by the Company at the end of the day on Friday, March 7, U.S. time. The Company then proceeded with issuance of the announcement on Monday morning, March 10.

    Feuerstein has been made aware that his information is incorrect, but refuses to apologize and retract. He may have overstepped. He has gone from journalism to purposely promulgating false information that has manipulated the stock price. This situation is so egregious that I would not be surprised to see the SEC get involved.
    Mar 12 11:00 AM | 11 Likes Like |Link to Comment
  • AF strikes again [View news story]
    Feuerstein has published clearly false and misleading information.

    He alleged that NWBO purposely delayed releasing news for two weeks on the approval of DCVax-L in Germany under the hospital exemption early access program. He states that this was done to manipulate the stock price by using the release as a “smokescreen” to divert attention away from other issues on the stock. If this allegation were correct, which it is not, would be a violation of securities law by NWBO.

    Northwest Biotherapeutics has just published a press release that shows that Feuerstein’s allegation is patently false and misleading. It clearly lays out the timeline that shows that the release of this information on March 10th was the earliest possible date that it could have done so. Feuerstein has clearly got this wrong and I would expect that he will apologize and issue a retraction.

    Northwest released a press release that clearly shows that his allegation that Northwest Biotherapeutics purposely delayed the announcement on the release of the German approval is patently false and misleading. The Company in its press release unequivocally refutes allegations made by Feuerstein in article published on Tuesday March 11. Feuerstein falsely accuses NW Bio of intentionally delaying the announcement of the Hospital Exemption approval by the Paul Ehrlich Institute (“PEI,” the FDA of Germany). Feuerstein’s accusations are factually wrong, materially misleading and reflect a lack of knowledge of German legal requirements relating to the PEI decision and the Company’s announcement.

    Feuerstein noted that the PEI decision was delivered to the Company on Friday, February 21. What Feuerstein failed to note was that the quite lengthy PEI decision document was delivered to the Company entirely in German. It required more than a week for the Company to receive the English translation. Due to the technical nature of the document, the Company had to obtain confirmation of the accuracy of the translation and confirm certain provisions of the approval. This process took several days.

    The final requirement under applicable German regulations was that the Company was required to obtain approval of the full English press release before releasing it. This was done by an independent Information Officer in Germany designated by PIE. The approval of the German reviewer was received by the Company at the end of the day on Friday, March 7, U.S. time. The Company then proceeded with issuance of the announcement on Monday morning, March 10.
    Mar 12 10:48 AM | 8 Likes Like |Link to Comment
  • Analysis: Northwest Biotherapeutics DCVax-L Germany Approval Under Hospital Exemption Early Access Program [View article]
    Remember that the bear case was that no credible people believe that DCVax-L can be effective and that it is probably no better than a placebo. Therefore the phase 3 trial is doomed to failure and will probably be stopped at an interim analysis for futility. This was the focus of two TheStreet.com articles last week written by F-Stein.

    We now have stunningly different information from the German equivalent of the FDA. They have looked at not only data for the phase 1/2 glioblastoma trials of 20 newly diagnosed GBM patients who received DCVax-L but also patients given the drug in the phase 1/2 prostate cancer and phase 1/2 ovarian cancer trials as well as patients treated with compassionate use. With their unique view into the data, they have seen things in this clinical data that led to this dramatic approval.

    F-stein was tweeting furiously yesterday trying to paint this news as inconsequential or negative and defending his short position.

    It is time for all investors to look at this company through the prism of the PEI action.
    Mar 11 09:53 AM | 8 Likes Like |Link to Comment
  • Northwest Biotherapeutics (NWBO, $6.06, Buy): Comments On First Interim Look At DCVax-L Trial And Recent Weakness In The Stock  [View instapost]
    F-stein is putting every negative spin possible out on Tweets. His arguments are ridiculous as usual but he does have his followers. However,today's news is so positive that I don't think he can bluster the stock down much.
    Mar 10 07:38 PM | Likes Like |Link to Comment
  • Northwest Biotherapeutics (NWBO, $6.06, Buy): Comments On First Interim Look At DCVax-L Trial And Recent Weakness In The Stock  [View instapost]
    Inferring things from interim looks has almost no precision.
    Mar 9 10:26 PM | Likes Like |Link to Comment
  • Northwest Biotherapeutics (NWBO, $6.06, Buy): Comments On First Interim Look At DCVax-L Trial And Recent Weakness In The Stock  [View instapost]
    F-stein did not call the ICT-107 trial result. His only comment was that he had an open mind on ICT-107 but was unequivocally certain that DCVax-L will fail. Here is what I said about that trial http://seekingalpha.co...
    Mar 9 10:25 PM | 1 Like Like |Link to Comment
  • Cadence: What To Do With The Proceeds And A Post Mortem On A Successful Investment [View article]
    Doesn't look like it, but your downside is $14.00.
    Mar 6 03:38 PM | Likes Like |Link to Comment
  • Antares Marketing Agreement With Leo On Otrexup Is A Nice Positive [View article]
    Otrexup was just launched four weeks ago and it is possible that he has not been called on by a rep. Here is some background info on Otrexup. http://bit.ly/1fVQRPU I hope that this may be of some benefit to you and your wife. Best wishes.
    Mar 5 09:04 PM | Likes Like |Link to Comment
  • Cytokinetics: Institutional Investors Give BENEFIT-ALS Potential Results A Vote Of Confidence [View article]
    Could you please refer me to your in-depth research on CYTK or have I just seen it?
    Mar 5 08:59 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
870 Comments
1,366 Likes